Payment overview · 2025
General Payments
$288.95
14 reported records · 9 companies
Healthcare provider profile · identity verified
Tarisha Renee Mixon, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BATON ROUGE, LA · NPI 1982915195
Verified facts
What the public records show
CMS Open Payments records show Tarisha Renee Mixon, M.D. received $288.95 in general payments during 2025 across 14 reported records.
Lilly USA, LLC accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $62.04 | 21.5% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $55.86 | 19.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.83 | 13.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.29 | 12.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $28.02 | 9.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.36 | 7.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.95 | 6.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.06 | 5.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.54 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $288.95 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $55.86 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $43.36 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.05 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $28.02 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 56 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 60 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 139 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
60 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
139 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 807 | 283 |
| Atorvastatin Calcium | Atorvastatin Calcium | 483 | 178 |
| Potassium Chloride | Potassium Chloride | 346 | 132 |
| Alprazolam | Alprazolam | 307 | 37 |
| Metformin Hcl | Metformin Hcl | 296 | 103 |
| Hydrochlorothiazide | Hydrochlorothiazide | 279 | 101 |
| Gabapentin | Gabapentin | 253 | 95 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 239 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 221 | 90 |
| Pravastatin Sodium | Pravastatin Sodium | 195 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 191 | 69 |
| Meloxicam | Meloxicam | 190 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 189 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 175 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 57 |
| Zolpidem Tartrate | Zolpidem Tartrate | 166 | 29 |
| Lisinopril | Lisinopril | 164 | 59 |
| Furosemide | Furosemide | 158 | 70 |
| Omeprazole | Omeprazole | 148 | 55 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 147 | 56 |
| Ozempic | Semaglutide | 140 | 28 |
| Metformin Hcl Er | Metformin Hcl | 139 | 50 |
| Mounjaro | Tirzepatide | 139 | 23 |
| Clonidine Hcl | Clonidine Hcl | 127 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 117 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 111 | 45 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 107 | 28 |
| Ibuprofen | Ibuprofen | 107 | 34 |
| Losartan Potassium | Losartan Potassium | 101 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 98 | 38 |
| Trazodone Hcl | Trazodone Hcl | 96 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 35 |
| Allopurinol | Allopurinol | 90 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 90 | 35 |
| Prednisone | Prednisone | 88 | 59 |
| Januvia | Sitagliptin Phosphate | 87 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 86 | 40 |
| Carvedilol | Carvedilol | 84 | 38 |
| Tramadol Hcl | Tramadol Hcl | 78 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 71 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 71 | 41 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 70 | 60 |
| Glimepiride | Glimepiride | 69 | 25 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 66 | 28 |
| Ezetimibe | Ezetimibe | 66 | 25 |
| Verapamil Er | Verapamil Hcl | 66 | 22 |
| Montelukast Sodium | Montelukast Sodium | 62 | 26 |
| Pregabalin | Pregabalin | 62 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 25 |
| Jardiance | Empagliflozin | 60 | 20 |
| Linzess | Linaclotide | 60 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 23 |
| Eliquis | Apixaban | 58 | 20 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 57 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 56 | 26 |
| Farxiga | Dapagliflozin Propanediol | 56 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 13 |
| Famotidine | Famotidine | 54 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 19 |
| Bumetanide | Bumetanide | 47 | 18 |
| Tradjenta | Linagliptin | 46 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 23 |
| Sertraline Hcl | Sertraline Hcl | 44 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 18 |
| Simvastatin | Simvastatin | 43 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 19 |
| Lovastatin | Lovastatin | 41 | 13 |
| Methocarbamol | Methocarbamol | 41 | 26 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | 15 |
| Diazepam | Diazepam | 40 | suppressed |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 14 |
| Spironolactone | Spironolactone | 40 | 18 |
| Buspirone Hcl | Buspirone Hcl | 39 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 39 | suppressed |
| Nifedipine Er | Nifedipine | 39 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | 22 |
| Clonazepam | Clonazepam | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 36 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | 12 |
| Benazepril Hcl | Benazepril Hcl | 35 | 11 |
| Azithromycin | Azithromycin | 34 | 29 |
| Promethazine Hcl | Promethazine Hcl | 34 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 14 |
| Irbesartan | Irbesartan | 31 | 11 |
| Mupirocin | Mupirocin | 31 | 22 |
| Ketoconazole | Ketoconazole | 30 | 21 |
| Ondansetron Odt | Ondansetron | 30 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 22 |
| Trulicity | Dulaglutide | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Belsomra | Suvorexant | 23 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 22 |
| Glipizide Er | Glipizide | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | 11 |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Valsartan | Valsartan | 21 | 11 |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | 11 |
| Glipizide | Glipizide | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 13 |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 12 |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 15 | 11 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Unithroid | Levothyroxine Sodium | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $288.95 · 14 records | Lilly USA, LLC | BREZTRI, CAPLYTA, FARXIGA, IBSRELA, JARDIANCE, MOUNJARO, QULIPTA, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error